WO2004089938A1 - A novel crystalline form of irbesartan - Google Patents
A novel crystalline form of irbesartan Download PDFInfo
- Publication number
- WO2004089938A1 WO2004089938A1 PCT/IN2003/000146 IN0300146W WO2004089938A1 WO 2004089938 A1 WO2004089938 A1 WO 2004089938A1 IN 0300146 W IN0300146 W IN 0300146W WO 2004089938 A1 WO2004089938 A1 WO 2004089938A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- irbesartan
- novel crystalline
- crystalline form
- ray powder
- powder diffraction
- Prior art date
Links
- YOSHYTLCDANDAN-UHFFFAOYSA-N CCCCC(N1Cc(cc2)ccc2-c(cccc2)c2-c2nnn[nH]2)=NC2(CCCC2)C1=O Chemical compound CCCCC(N1Cc(cc2)ccc2-c(cccc2)c2-c2nnn[nH]2)=NC2(CCCC2)C1=O YOSHYTLCDANDAN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Definitions
- the present invention relates to a novel crystalline form of irbesartan, to process for its preparation and a pharmaceutical composition containing it.
- the object of the present invention is to provide a stable novel crystalline form of irbesartan, a process for preparing it and a pharmaceutical composition containing it.
- a novel crystalline form of irbesartan designated as form C, characterized by an x-ray powder diffraction pattern having peaks expressed as 2 ⁇ at about 8.3, 8.7, 10.1, 11.8, 15.0, 15.5, 16.4, 16.8, 17.5, 18.3, 19.1, 20.3, 21.1, 21.7, 23.6, 25.1, 25.5, 26.4, 26.8, 27.2, 28.1, 29.0 and 29.4 degrees.
- Figure 1 shows typical form C x-ray powder diffraction spectrum.
- irbesartan is mixed with a suitable solvent and irbesartan form C is isolated from the mixture.
- a suitable solvent is heated to reflux and the contents are filtered at about 5°C to 25°C.
- the suitable solvent is tetrahydrofuran or 1,4-dioxane; or a mixture thereof.
- Suitable solvent mixed with any other solvent/s like water may be used as long as irbesartan form C can be isolated from the solvent mixture.
- Previously known form of irbesartan or irbesartan prepared by a known method may be used in the process.
- a pharmaceutical composition comprising irbesartan form C.
- Irbesartan form C may be formulated in a form suitable for oral administration or injection.
- Figure 1 is a x-ray powder diffraction spectrum of irbesartan form C. x-Ray powder diffraction spectrum was measured on a Siemens D5000 x- ray powder diffractometer having a copper-K ⁇ radiation.
- Example 1 Irbesartan (5.0 gm, obtained by the process described in example 5 of US 5,270,317) is mixed with tetrahydrofuran (350 ml), heated to reflux and maintained under reflux temperature for 30 minutes. The contents are cooled to 10°C. The separated crystals are collected by filtration to give 4.2 gm irbesaratan form C.
- Example 2 Example 1 is repeated using irbesartan form A for irbesartan to give irbesartan form C.
- Example 3 Example 1 is repeated using irbesartan form B for irbesartan to give irbesartan form C.
- Example 4 The mixture of Irbesartan (5.0 gm, obtained by process described in example 5 of US 5,270,317) and 1.4-dioxane (100 ml) is stirred for 5 hours at 20°C to 25°C. The solid is collected by filtration to give 4.7 gm irbesaratan form C.
- Example 5 Irbesartan (5.0 gm, obtained by process described in example 5 of US
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2003/000146 WO2004089938A1 (en) | 2003-04-07 | 2003-04-07 | A novel crystalline form of irbesartan |
AU2003242984A AU2003242984A1 (en) | 2003-04-07 | 2003-04-07 | A novel crystalline form of irbesartan |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2003/000146 WO2004089938A1 (en) | 2003-04-07 | 2003-04-07 | A novel crystalline form of irbesartan |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004089938A1 true WO2004089938A1 (en) | 2004-10-21 |
Family
ID=33156190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2003/000146 WO2004089938A1 (en) | 2003-04-07 | 2003-04-07 | A novel crystalline form of irbesartan |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003242984A1 (en) |
WO (1) | WO2004089938A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006050923A1 (en) * | 2004-11-11 | 2006-05-18 | Lek Pharmaceuticals D.D. | Polymorph form of irbesartan |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0420237A1 (en) * | 1989-09-29 | 1991-04-03 | Eisai Co., Ltd. | Biphenylmethane derivative, the use of it and pharmacological compositions containing same |
EP0475898A1 (en) * | 1990-09-10 | 1992-03-18 | Ciba-Geigy Ag | Azacyclic compounds |
US5629331A (en) * | 1994-10-19 | 1997-05-13 | Sanofi | Process for the preparation of a tetrazole derivative in two crystalline forms and novel the crystalline forms thereof |
-
2003
- 2003-04-07 WO PCT/IN2003/000146 patent/WO2004089938A1/en not_active Application Discontinuation
- 2003-04-07 AU AU2003242984A patent/AU2003242984A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0420237A1 (en) * | 1989-09-29 | 1991-04-03 | Eisai Co., Ltd. | Biphenylmethane derivative, the use of it and pharmacological compositions containing same |
EP0475898A1 (en) * | 1990-09-10 | 1992-03-18 | Ciba-Geigy Ag | Azacyclic compounds |
US5629331A (en) * | 1994-10-19 | 1997-05-13 | Sanofi | Process for the preparation of a tetrazole derivative in two crystalline forms and novel the crystalline forms thereof |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006050923A1 (en) * | 2004-11-11 | 2006-05-18 | Lek Pharmaceuticals D.D. | Polymorph form of irbesartan |
Also Published As
Publication number | Publication date |
---|---|
AU2003242984A1 (en) | 2004-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI114156B (en) | A process for the preparation of a tetrazole derivative in two crystalline forms and a novel crystalline form of said derivative | |
EP2176253B1 (en) | A process for the preparation or purification of olmesartan medoxomil or olmesartan medoxomil hydrohalide salt | |
US7504516B2 (en) | Crystalline forms of candesartan cilexetil | |
CN101565394A (en) | Crystalline forms of atorvastatin | |
US20050119328A1 (en) | Novel crysalline forms of tegaserod maleate | |
WO2004089938A1 (en) | A novel crystalline form of irbesartan | |
EP1589966B1 (en) | Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods | |
CA2060825A1 (en) | Therapeutic agent | |
US20090233932A1 (en) | Novel crystalline forms of lamotrigine | |
CA2482857A1 (en) | Processes for preparing losartan and losartan potassium | |
US20090192318A1 (en) | Method of preparation of N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-y1) [1,1'-biphenyl]-4-y1]methyl]-L-valine (valsartan) | |
WO2004087681A1 (en) | A novel amorphous form of valsartan | |
WO2007041414A1 (en) | Methods of preparing anhydrous aripiprazole form ii | |
US20090227645A1 (en) | Pharmaceutical compositions of valdecoxib | |
US20050154052A1 (en) | Novel crystalline forms of (s)-citalopram oxalate | |
CA2541379A1 (en) | Losartan potassium crystalline form alpha | |
WO2008041957A1 (en) | Method for producing pure crystalline form of 2-n-butyl-3-((2-(1h-tetrazole-5-yl) (1,1'-biphenyl)-4-methyl)-1,3-diazapspiro (4,4') non -1- en-4-one | |
US6916935B2 (en) | Losartan potassium synthesis | |
EP2022790A1 (en) | A process for the preparation or purification of olmesartan medoxomil | |
WO2004089957A1 (en) | A novel crystalline form of dorzolamide hydrochloride | |
EP1608641A1 (en) | A process for the synthesis of losartan potassium | |
WO2004083230A1 (en) | Novel crystalline forms of finasteride |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |